BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hernandez-Unzueta I, Benedicto A, Olaso E, Sanz E, Viera C, Arteta B, Márquez J. Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncol Lett 2017;13:4002-12. [PMID: 28599406 DOI: 10.3892/ol.2017.6016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Benedicto A, Sanz E, Márquez J. Ocoxin as a complement to first line treatments in cancer. Int J Med Sci 2021;18:835-45. [PMID: 33437220 DOI: 10.7150/ijms.50122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hernández-SanMiguel E, Gargini R, Cejalvo T, Segura-Collar B, Núñez-Hervada P, Hortigüela R, Sepúlveda-Sánchez JM, Hernández-Laín A, Pérez-Núñez A, Sanz E, Sánchez-Gómez P. Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma. Oxid Med Cell Longev 2019;2019:9719730. [PMID: 31467641 DOI: 10.1155/2019/9719730] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
3 Fundora Ramos MI, Maden LB, Casanova FO, Cruz FH, Reyes CS, Gato AH, Lyncon IB, González EV, Morales KP, Lence JJ, Sanz E. Oncoxin-Viusid® may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. Mol Clin Oncol 2021;14:5. [PMID: 33235733 DOI: 10.3892/mco.2020.2167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Pandiella A, Sanz E, Díaz-Rodríguez E. Ocoxin oral solution demonstrates antiviral properties in cellular models. Exp Ther Med 2021;22:1127. [PMID: 34504579 DOI: 10.3892/etm.2021.10561] [Reference Citation Analysis]
5 Hernandez-Unzueta I, Benedicto A, Romayor I, Herrero A, Sanz E, Arteta B, Olaso E, Márquez J. Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance. Pancreas 2019;48:555-67. [PMID: 30946238 DOI: 10.1097/MPA.0000000000001277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
6 Benedicto A, Hernandez-Unzueta I, Sanz E, Márquez J. Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma. Nutrients 2021;13:686. [PMID: 33669949 DOI: 10.3390/nu13020686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Pandiella-Alonso A, Díaz-Rodríguez E, Sanz E. Antitumoral Properties of the Nutritional Supplement Ocoxin Oral Solution: A Comprehensive Review. Nutrients 2020;12:E2661. [PMID: 32878230 DOI: 10.3390/nu12092661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Pérez-Peña J, Díaz-Rodríguez E, Sanz E, Pandiella A. Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin. Nutrients 2019;11:E1068. [PMID: 31091680 DOI: 10.3390/nu11051068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Prester L, Mikolić A, Jurič A, Fuchs N, Neuberg M, Lucić Vrdoljak A, Brčić Karačonji I. Effects of Δ9-tetrahydrocannabinol on irinotecan-induced clinical effects in rats. Chem Biol Interact 2018;294:128-34. [PMID: 30130528 DOI: 10.1016/j.cbi.2018.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]